Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Financial Flexibility Index
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a Financial Flexibility Index of -0.12x as of March 2026. Free cash flow of $-349.69K (operating CF $-349.69K minus capex $0.00) represents 0% of total liabilities ($3.04 Million). Check Lakewood-Amedex Biotherapeutics Inc. Com liquidity resilience to evaluate the company's liquid asset resilience ratio.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lakewood-Amedex Biotherapeutics Inc. Common Stock Financial Flexibility Index (2023–2025)
Historical Financial Flexibility Index trend for Lakewood-Amedex Biotherapeutics Inc. Common Stock across 3 annual periods. Explore Lakewood-Amedex Biotherapeutics Inc. Com (LABT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Financial Flexibility Index for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
Year-by-year free cash flow to debt coverage for Lakewood-Amedex Biotherapeutics Inc. Common Stock. For the full cash flow conversion analysis, see LABT cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.80x | $-1.94 Million | $-1.94 Million | $2.45 Million | ▲ +90.8% |
| 2024 | -8.66x | $-5.72 Million | $-5.72 Million | $660.97K | ▼ -196.6% |
| 2023 | -2.92x | $-6.82 Million | $-6.82 Million | $2.34 Million | — |